Andrade’s syndrome, historically recognized as familial amyloid polyneuropathy type I, represents a severe, autosomal dominant neurodegenerative and systemic disorder characterized by the extracellular deposition of misfolded transthyretin amyloid fibrils. First meticulously documented in coastal northern Portugal, this debilitating condition bridges clinical neurology, molecular genetics, and multisystem internal medicine, illustrating the destructive potential of aberrant protein folding on the peripheral and autonomic nervous systems.
Andrade’s Syndrome
1. Concise Definition
Andrade’s syndrome is a rare, life-threatening hereditary disorder caused by point mutations in the transthyretin (TTR) gene, culminating in the systemic deposition of amyloid fibrils within peripheral nerves, autonomic fibers, the gastrointestinal tract, the heart, and the kidneys. Clinically, it manifests as an insidiously progressive sensorimotor and autonomic neuropathy that typically initiates in the lower extremities and inexorably advances toward severe physical disability, cachexia, and early mortality if left untreated.
From a pathophysiological standpoint, the condition is classified within the spectrum of variant transthyretin-mediated (ATTRv) amyloidosis. The replacement of a single amino acid—most notoriously valine by methionine at position 30 (Val30Met or p.Val50Met)—destabilizes the native homotetrameric conformation of the circulating transthyretin transport protein. Dissociated monomers undergo partial denaturation, self-assembly, and aggregation into beta-sheet-rich fibrillar structures that infiltrate delicate extracellular matrices, leading directly to axonal degeneration, organ dysfunction, and catastrophic autonomic collapse.
2. Etymology & Linguistic Origin
The eponym honors Dr. Mário Corino da Costa Andrade (1906–2005), a pioneering Portuguese neurologist who first characterized the clinical entity systematically in the mid-twentieth century. The word "syndrome" derives from the Ancient Greek syndromē (συνδρομή), signifying "a running together" or "concurrence," compounded from syn- (together) and dromos (a course or run), highlighting the complex constellation of concurrent neurological, gastrointestinal, and systemic symptoms presenting in affected patients.
Within modern nosology, Andrade’s syndrome is frequently designated as Familial Amyloidotic Polyneuropathy (FAP) type I, or Portuguese-type hereditary amyloidosis. The linguistic shift in recent biochemical and clinical literature favors genotypic classification, referring to the entity as hereditary transthyretin amyloidosis (ATTRv amyloidosis, where "v" designates "variant" to distinguish it from wild-type age-related ATTRwt). Nevertheless, the historical eponym retains immense academic and diagnostic currency, recognizing the classic early-onset phenotype originating from coastal European cohorts.
3. Pronunciation & Grammatical Form
The term is pronounced in English as /ænˈdrɑːdəz ˈsɪndroʊm/ (an-DRAH-dəz SIN-drohm). Grammatically, it functions as a compound proper noun phrase. The adjectival possessive form "Andrade’s" precedes the singular countable noun "syndrome." In formal medical literature, it may appear without the apostrophe as "Andrade syndrome" or adjectivally in phrasing such as "Andrade-type polyneuropathy."
Derived linguistic forms include "amyloidogenic" (/ˌæmɪlɔɪdəˈdʒɛnɪk/), describing the pathological propensity of the variant transthyretin monomers to self-aggregate, and "transthyretin-related," which is utilized to categorize both the localized and generalized variants of the disease process. The noun form "amyloidosis" (/ˌæmɪlɔɪˈdoʊsɪs/) describes the overarching pathological state defined by systemic amyloid deposition.
4. Detailed Conceptual Explanation
To fully grasp Andrade’s syndrome, one must examine both molecular biophysics and clinical neuroanatomy. Transthyretin is a 55-kilodalton homotetrameric serum transport protein synthesized predominantly by the liver parenchymal cells and, to a lesser extent, the choroid plexus and retinal pigment epithelium. Under normal physiological circumstances, its quaternary structure is exceptionally stable, serving to transport thyroxine (T4) and retinol-binding protein-vitamin A complexes throughout the vascular and cerebrovascular compartments.
In patients carrying the pathogenic genetic variant associated with Andrade’s syndrome, an amino acid substitution—most classically the Val30Met alteration—destabilizes the energetic landscape of the tetramer. This alteration drastically reduces the kinetic barrier required for the tetramer to dissociate into its constituent monomers. Once dissociated, these unstable monomers rapidly misfold into non-native intermediate conformations. Through a nucleation-dependent polymerization mechanism, these misfolded intermediates aggregate into non-branching, antiparallel beta-sheet fibrils measuring approximately 7 to 10 nanometers in diameter.
These insolubilized fibrils accumulate progressively in the interstitial space of peripheral nerve trunks, unmyelinated autonomic nerve bundles, sensory ganglia, and essential viscera. Within the peripheral nervous system, amyloid deposits exert direct mechanical pressure and induce focal microvascular ischemia by infiltrating the endoneurial and epineurial blood vessels. Simultaneously, amyloid oligomers exert direct toxic effects on Schwann cells and axonal membranes, generating oxidative stress and triggering localized neuroinflammation.
The spatial and temporal progression of Andrade’s syndrome follows a stereotypical pattern. The disease typically commences in the small, unmyelinated C-fibers and thinly myelinated A-delta fibers responsible for conveying thermal sensations and nociception. As a consequence, patients initially experience symmetric loss of temperature sensitivity and pinprick pain sensation in the distal lower extremities, often accompanied by excruciating neuropathic pain, dysesthesias, and hyperalgesia. As large-diameter myelinated sensory and motor fibers become involved, vibratory sensation, proprioception, and motor control deteriorate, leading to sensory ataxia, progressive foot drop, distal muscle atrophy, and profound gait disturbances.
Simultaneously, relentless autonomic nervous system involvement creates debilitating systemic disability. Denervation of the cardiovascular adrenergic and vagal pathways leads to severe orthostatic hypotension, postprandial syncope, and chronotropic incompetence. Gastrointestinal dysmotility manifests as alternating bouts of intractable secretory diarrhea and severe constipation, delayed gastric emptying (gastroparesis), recurrent nausea, early satiety, and progressive cachexia. Dysautonomia further extends to neurogenic bladder dysfunction, marked by urinary retention, recurrent infections, and early erectile dysfunction in men, painting a holistic picture of systemic biological devastation.
5. Historical Development
The clinical identification of Andrade’s syndrome represents a landmark milestone in twentieth-century neurogenetics. In the late 1930s and 1940s, Dr. Mário Corino da Costa Andrade observed an unusual and uniform neurodegenerative disease among fishermen and agricultural workers originating from Póvoa de Varzim, a coastal town in northern Portugal. These patients presented with a devastating triad of peripheral polyneuropathy, dysautonomia, and progressive wasting, frequently terminating in death within a decade of symptom onset.
In 1952, Andrade published his seminal monographic study in Brain, detailing 74 cases of this novel clinical entity under the title "A Peculiar Form of Peripheral Neuropathy." He demonstrated the hereditary nature of the disease, established its autosomal dominant transmission pattern, and identified Congo red-positive amyloid deposits in peripheral nerves and visceral organs obtained from post-mortem examinations. Andrade’s meticulous histopathological correlations definitively separated this condition from other familial neuropathies, such as Charcot-Marie-Tooth disease, establishing it as a distinct amyloidotic disorder.
Subsequent decades unraveled the molecular and biochemical architecture of the syndrome. In the late 1970s, researchers discovered that the amyloid fibril protein in Portuguese families was immunochemically identical to prealbumin, which was subsequently renamed transthyretin. By 1984, molecular biologists pinpointed the precise genetic etiology: a point mutation in exon 2 of the TTR gene located on chromosome 18q12.1, resulting in the substitution of valine by methionine at codon 30. This discovery catalyzed genetic screening, enabling presymptomatic diagnosis and opening modern avenues for targeted disease-modifying therapies.
6. Theoretical Foundations
The pathological framework of Andrade’s syndrome is firmly rooted in the overarching paradigm of protein misfolding diseases, also known as proteopathies or conformational diseases. This theoretical framework posits that biological functional integrity relies not merely on primary amino acid sequences, but strictly on the precise, thermodynamically stable three-dimensional tertiary and quaternary arrangements of functional polypeptides.
Within this framework, the disease demonstrates the classic concept of a "kinetic trap" in protein folding energetics. The wild-type transthyretin tetramer maintains a robust energy well that prevents spontaneous disassembly under standard physiological pH and temperature. The introduction of the Val30Met substitution perturbs the quaternary interface between dimer pairs, substantially lowering the activation energy barrier for tetrameric dissociation. This conformational shift exemplifies how a minor primary-structure mutation produces catastrophic quaternary structural instability, transitioning functional transport proteins into pathotoxically stable beta-sheet aggregates.
Furthermore, contemporary neurobiological frameworks emphasize the "two-hit" hypothesis of amyloid-mediated neurotoxicity. The first phase involves the biochemical toxicity exerted by intermediate, soluble non-fibrillar oligomers, which disrupt local cellular membrane integrity, induce intracellular calcium influx, generate reactive oxygen species, and trigger apoptosis in Schwann cells and small dorsal root ganglion neurons. The second phase involves the physical, mechanical space-occupying properties of dense fibrillar amyloid conglomerates, which entrap axons, strangulate microcirculation within the endoneurium, and cause dense structural ischemic necrosis across nerve bundles.
7. Key Components, Types & Dimensions
Andrade’s syndrome presents with structured clinical dimensions and molecular variations that govern its phenotypic heterogeneity:
- Sensory Neuropathy: A hallmark initial component characterized by the preferential loss of thermal and pain sensations (small-fiber predilection) following a classic stocking-and-glove distribution, accompanied by severe spontaneous burning neuropathic pain, dysesthesia, and allodynia.
- Autonomic Neuropathy: Early, severe involvement of sympathetic and parasympathetic networks resulting in profound orthostatic hypotension, dyshidrosis (inability to sweat properly), neurogenic bladder dysfunction, erectile dysfunction, and devastating gastrointestinal motility disturbances ranging from obstipation to life-threatening chronic watery diarrhea.
- Motor Neuropathy: Late-stage involvement of large-diameter motor axons resulting in distal symmetric lower motor neuron weakness, muscular atrophy (predominantly in the intrinsic foot muscles and peroneal compartment), bilateral foot drop, hand intrinsic wasting, loss of deep tendon reflexes, and eventual complete immobility.
- Cardiomyopathy Dimension: Myocardial infiltration by amyloid fibrils causing progressive concentric biventricular wall thickening, restrictive cardiomyopathy, low voltage on electrocardiography despite marked echocardiographic hypertrophy, conduction blocks requiring pacemaker implantation, and diastolic heart failure.
- Ocular and Vitreous Infiltration: Deposition of amyloid fibrils produced locally by the retinal pigment epithelium into the vitreous body ("glass wool" vitreous opacities), secondary glaucoma, retinal microangiopathy, and pupillary abnormalities such as scalloped margins.
- Nephropathy Dimension: Renal amyloid infiltration leading to progressive microalbuminuria, overt nephrotic syndrome, and chronic renal failure due to glomular and vascular amyloid accumulation.
- Phenotypic Subtypes (Chronological):
- Early-Onset (Classic Portuguese Phenotype): Typically begins in the third to fourth decade of life (mean age ~30–35), marked by prominent small-fiber polyneuropathy, catastrophic autonomic dysfunction, high penetrance, and classic Val30Met mutation.
- Late-Onset Phenotype: Typically manifests after age 50 or 60 (frequently documented in northern Sweden and non-endemic global populations), characterized by less severe autonomic involvement, prominent motor and large-fiber sensory deficits, early cardiac infiltration, and variable penetrance.
8. Examples & Illustrative Cases
Consider the classic clinical trajectory of a 32-year-old male native to northern Portugal whose maternal uncle succumbed to an undiagnosed progressive wasting disease at age 42. The patient presents initially with bilateral sensory blunting to hot water in his feet, having sustained painless burn blisters while walking on hot sand. Simultaneously, he notes alternating bouts of postprandial nausea, early satiety, and spontaneous watery diarrhea occurring up to six times daily, alongside persistent lightheadedness whenever standing abruptly from a seated position.
Physical examination confirms profound orthostatic hypotension, with a systolic blood pressure drop of 40 mmHg upon standing without an appropriate compensatory tachycardia. Neurological examination reveals a symmetrical loss of pinprick and temperature discrimination from the toes to the mid-calf, while vibratory sensation, proprioception, and motor strength remain intact. Nerve conduction studies exhibit normal large-fiber conduction velocities, but specialized quantitative sensory testing and skin biopsy measuring intraepidermal nerve fiber density (IENFD) reveal severe small-fiber depletion. Genetic analysis confirms heterozygosity for the TTR Val30Met pathogenic variant, validating the diagnosis of early-stage Andrade’s syndrome.
In contrast, consider an illustrative late-onset case: a 66-year-old female of Swedish descent presenting with progressive bilateral lower extremity weakness, loss of joint position sense, sensory ataxia, and exertional dyspnea. Unlike the Portuguese patient, her autonomic symptoms are mild, but an echocardiogram reveals severe symmetrical left ventricular wall thickening with a preserved ejection fraction, accompanied by apical sparing on longitudinal strain analysis. Biopsy of the salivary gland confirms apple-green birefringence under polarized light after Congo red staining, and genetic sequencing discloses the same Val30Met mutation, illustrating the marked phenotypic divergence shaped by geographical origins, age of onset, and genetic modifiers.
9. Measurement & Assessment
Evaluating and staging Andrade’s syndrome requires multimodal diagnostic and assessment methodologies spanning genetics, histology, neurophysiology, and cardiology:
- Molecular Genetic Testing: The gold standard for definitive diagnosis. Direct DNA sequencing of the TTR gene evaluates all four exons to identify point mutations, primarily the c.148G>A (p.Val50Met, historically known as Val30Met) mutation, alongside more than 130 other amyloidogenic variants.
- Tissue Biopsy and Histochemical Staining: Histological demonstration of amyloid deposition remains a crucial confirmatory tool. Tissue is harvested from accessible sites such as abdominal subcutaneous fat aspirates, minor labial salivary glands, the sural nerve, or rectal mucosa. Microscopic examination utilizing Congo red staining reveals pathognomonic bright apple-green birefringence under polarized light illumination. Immunohistochemistry or mass spectrometry-based proteomic analysis confirms the amyloid fibrils are composed specifically of transthyretin.
- Neurophysiological Evaluation: Comprehensive nerve conduction studies (NCS) and electromyography (EMG) assess large-fiber sensory and motor axonal loss. In early stages, conventional NCS may remain normal due to isolated small-fiber disease; hence, quantitative sensory testing (QST), autonomic reflex screens (including tilt-table testing, Valsalva ratio, and Quantitative Sudomotor Axon Reflex Testing [QSART]), and skin biopsies assessing intraepidermal nerve fiber density are essential for early detection.
- Clinical Disability Staging Systems: The Coutinho Staging System is universally employed to quantify clinical progression:
- Stage 0: Asymptomatic carrier with confirmed mutation.
- Stage 1: Unimpaired ambulation; sensory and autonomic symptoms localized mostly to lower extremities.
- Stage 2: Impaired ambulation; assistance required (cane, crutches, or walker) due to progressive motor weakness and ataxia.
- Stage 3: Confined to a wheelchair or bedridden; severe motor, sensory, and autonomic cachexia.
- Cardiac and Systemic Imaging: Transthoracic echocardiography, cardiac magnetic resonance imaging (CMR) with late gadolinium enhancement, and bone scintigraphy using technetium-labeled radiotracers (99mTc-PYP, 99mTc-DPD, or 99mTc-HMDP) yield exceptional sensitivity for identifying preclinical and clinical cardiac transthyretin infiltration.
10. Applications & Practical Significance
The clinical and therapeutic landscape of Andrade’s syndrome has undergone an extraordinary paradigm shift over the past three decades, transforming from a universally fatal condition managed exclusively with supportive palliatives to a benchmark model for modern targeted therapeutics in precision medicine.
Historically, orthotopic liver transplantation emerged in 1990 as the first disease-modifying intervention. Because the liver produces more than 99% of circulating plasma transthyretin, replacing the patient’s liver with a donor liver removes the primary source of the variant amyloidogenic protein, effectively halting progressive peripheral neuropathy in early-onset Val30Met cases. However, transplantation is associated with substantial perioperative morbidity, requires lifelong immunosuppression, and fails to stop amyloid progression in the heart, where wild-type transthyretin continues to deposit onto pre-existing amyloid templates.
The modern therapeutic era focuses on pharmacotherapeutic intervention across three distinct molecular mechanisms: kinetic tetramer stabilization, gene silencing, and amyloid fibril disruption. Tetramer stabilizers, such as tafamidis, bind selectively to the thyroxine-binding pockets of circulating transthyretin, stabilizing its quaternary structure and preventing its dissociation into amyloidogenic monomers. Tafamidis was demonstrated to significantly slow neurological deterioration and reduce mortality, securing international regulatory approvals.
Gene-silencing technologies have revolutionized patient management by degrading hepatic transthyretin messenger RNA. Small interfering RNA (siRNA) agents like patisiran and vutrisiran, along with antisense oligonucleotides (ASOs) such as inotersen and eplontersen, dramatically decrease total circulating transthyretin levels by up to 80% to 90%. Clinical trials have demonstrated not only arrest of neuropathic progression in Stage 1 and Stage 2 Andrade’s syndrome, but even reversal of neurological deficits and improvement in autonomic quality of life, positioning these treatments at the vanguard of RNA-targeted medicine.
11. Research & Empirical Evidence
Empirical evidence documenting the progression and treatment of Andrade’s syndrome rests upon multi-decade natural history registries and multinational randomized controlled clinical trials. Foundational epidemiological research led by Planté-Bordeneuve, Conceição, and colleagues established that without targeted therapeutic intervention, the median survival from symptom onset ranges from 10 to 15 years, with end-stage mortality universally resulting from cachexia, severe autonomic failure, sudden cardiac death, or secondary infectious complications.
The landmark clinical trial by Coelho et al. (2012) published in Neurology evaluated tafamidis in early-stage Val30Met patients, demonstrating that 65.3% of treated patients maintained neurological stability compared to only 37.1% in the placebo group over 18 months, as quantified by the Neuropathy Impairment Score-Lower Limbs (NIS-LL). Subsequent long-term open-label extensions confirmed that early treatment initiation preserves functional independence and substantially prolongs survival.
The pivotal APOLLO trial (Adams et al., 2018), published in The New England Journal of Medicine, evaluated the efficacy of the RNA interference agent patisiran in hereditary transthyretin amyloidosis with polyneuropathy. The study demonstrated that patisiran not only met its primary endpoint—halting the progression of neuropathy measured by the modified Neuropathy Impairment Score +7 (mNIS+7)—but remarkably produced a mean decrease in the score, indicating genuine neurophysiological recovery. Simultaneously, the NEURO-TTR trial (Benson et al., 2018) verified the efficacy of the antisense oligonucleotide inotersen, demonstrating significant stabilization of neuropathic progression and quality-of-life indices compared with placebo.
12. Cultural & Cross-Cultural Considerations
Andrade’s syndrome exhibits dramatic geographic clustering and remarkable cross-cultural variability in clinical presentation and genetic penetrance. The classic endemic foci are concentrated in northern Portugal (specifically around Póvoa de Varzim and Vila do Conde), specific islands of Japan (such as Nagano and Kumamoto), northern Sweden (Skellefteå and Piteå), and parts of Brazil, Cyprus, and Majorca (Spain).
Intriguingly, genetic penetrance diverges markedly across these regional populations despite identical Val30Met mutations. In northern Portugal, the disease demonstrates high penetrance, with over 80% of mutation carriers manifesting clinical disease by age 50, presenting predominantly with the early-onset, autonomic-heavy phenotype. In contrast, in northern Sweden, the carrier rate is remarkably high (approaching 1.5% of the regional population), but penetrance is exceptionally low, with less than 5% developing clinical symptoms by age 40, and the majority manifesting late-onset disease characterized by large-fiber neuropathy and cardiopathy after age 60.
This striking divergence emphasizes the profound impact of epigenetic factors, environmental modulators, and non-coding genetic modifier loci that vary across ethnic and geographic populations. Culturally, in tightly knit endemic communities like Póvoa de Varzim, the disease historically carried profound social stigma, referred to colloquially as mal dos pés ("foot sickness"). Generations of affected families faced intense psychological burdens, marriage avoidance, and economic destitution, giving rise to specialized hereditary disease registries, regional genetic counseling centers, and community support foundations that remain pivotal today.
13. Criticisms, Debates & Limitations
Despite astonishing therapeutic and genetic advancements, clinical debates and unresolved challenges persist in the field of Andrade’s syndrome. A major clinical controversy surrounds the timing of therapeutic initiation in asymptomatic carriers. Because novel genetic therapies (such as siRNAs and ASOs) and stabilizers are exceptionally expensive and may carry long-term monitoring demands, determining the exact biomarker-driven inflection point—when an asymptomatic carrier transitions to active, microscopic amyloid tissue damage—remains a subject of intense academic debate.
Another significant debate centers on the progression of central nervous system (CNS) and ocular amyloidosis. Circulating genetic therapies and liver transplants effectively reduce liver-derived transthyretin in the systemic circulation, but they cannot cross the blood-brain barrier or the blood-retinal barrier. Because the choroid plexus and retinal pigment epithelium independently synthesize mutant transthyretin, long-term survivors are increasingly presenting with late ocular amyloidosis (vitreous opacity, glaucoma) and cerebral amyloid angiopathy (CAA) leading to transient focal neurological episodes, intracranial hemorrhages, and cognitive impairment. Addressing this pharmacoresistant CNS sanctuary site represents one of modern medicine’s greatest hurdles.
Furthermore, socio-economic and global equity issues remain contentious. The exorbitant financial cost of next-generation RNA therapies places them out of reach for health systems in developing nations and imposes severe strains on public health resources in endemic countries like Portugal and Brazil. Critics emphasize that while the molecular biology of Andrade’s syndrome is a triumphant success story, global healthcare inequality threatens to deny these life-saving advancements to those populations where the disease was initially discovered.
14. Related Terms & Distinctions
Understanding Andrade’s syndrome requires clear differentiation from other amyloidotic and neuropathic entities:
- ATTRwt Amyloidosis (Wild-Type Transthyretin Amyloidosis): Formerly known as senile systemic amyloidosis, this condition arises from the misfolding of unmutated, wild-type transthyretin, predominantly in elderly men (>70 years). It presents primarily as an isolated restrictive cardiomyopathy or carpal tunnel syndrome, without the severe, early hereditary polyneuropathy characteristic of Andrade’s syndrome.
- AL Amyloidosis (Light Chain Amyloidosis): A plasma cell dyscrasia characterized by the systemic deposition of monoclonal immunoglobulin light chains. While it can produce severe autonomic and sensory neuropathy mimicking Andrade’s syndrome, its clinical course is markedly more acute, lacks a familial inheritance pattern, and requires chemotherapy or autologous stem cell transplantation.
- Charcot-Marie-Tooth Disease (CMT): A broad group of inherited peripheral neuropathies (predominantly CMT1 and CMT2). CMT is typically slowly progressive over decades, primarily damages motor and large-fiber sensory axons without prominent dysautonomia, does not involve amyloid fibrils, and has no associated cardiac or gastrointestinal deposition.
- Diabetic Autonomic Neuropathy: A common secondary metabolic complication of diabetes mellitus that closely mirrors the sensory loss and dysautonomia of Andrade’s syndrome. Differentiation relies on clinical history, fasting glycemia, absence of family history, and genetic confirmation of the TTR variant.
- Familial Amyloid Polyneuropathy Types II, III, and IV: Historical phenotypic classifications representing non-transthyretin hereditary amyloidoses, including gelsolin amyloidosis (FAP type IV / Meretoja’s syndrome) and apolipoprotein A-I amyloidosis (FAP type III), which exhibit distinct facial neuropathies, corneal lattice dystrophy, or nephropathic patterns rather than the classic lower extremity-predominant polyneuropathy described by Andrade.
15. Summary / Key Takeaways
Andrade’s syndrome is an autosomal dominant, life-threatening systemic proteopathy caused by mutations in the transthyretin (TTR) gene—most notably the Val30Met substitution. Characterized pathologically by the systemic deposition of extracellular amyloid fibrils, it manifests clinically as an unrelenting length-dependent sensorimotor polyneuropathy, catastrophic autonomic dysfunction, cardiac infiltration, and wasting cachexia. Historically termed familial amyloid polyneuropathy type I following its seminal discovery by Dr. Mário Corino de Andrade in 1952, the disease has become the archetypal clinical model for deciphering protein misfolding biophysics and implementing targeted genomic interventions. Today, modern therapeutic modalities—including kinetic tetramer stabilizers and cutting-edge RNA-interference gene silencers—have revolutionized its prognosis, turning an inexorably fatal neurodegenerative disorder into a manageable chronic disease.
References
- Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C. C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., Lin, K. P., Vita, G., Attarian, S., Planté-Bordeneuve, V., Mezei, M. M., Campistol, J. M., Buades, J., Brannagan, T. H., Kim, B. J., … Suhr, O. B. (2018). Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. The New England Journal of Medicine, 379(1), 11–21. https://doi.org/10.1056/NEJMoa1716153
- Andrade, C. (1952). A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain: A Journal of Neurology, 75(3), 408–427. https://doi.org/10.1093/brain/75.3.408
- Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Maurer, M. S., Scheinberg, F. A., Wieling, W., Hazenberg, B. P. C., Monia, B. P., Schneider, E., Yureneva, E., Geary, R. S., McCaleb, M. L., Libassi, A., & Coelho, T. (2018). Inotersen treatment for patients with hereditary transthyretin amyloidosis. The New England Journal of Medicine, 379(1), 22–31. https://doi.org/10.1056/NEJMoa1716793
- Coelho, T., Maia, L. F., Martins da Silva, A., Waddington Cruz, M., Planté-Bordeneuve, V., Lozeron, P., Suhr, O. B., Campistol, J. M., Conceição, I. M., Schmidt, H. H., Trigo, P., Kelly, J. W., Labaudinière, R., Chan, J., Packman, J., Wilson, D. J., & Grogan, D. R. (2012). Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial. Neurology, 79(8), 785–792. https://doi.org/10.1212/WNL.0b013e3182661ebf
- Conceição, I., González-Duarte, A., Obici, L., Schmidt, H. H., Simoneau, D., Chou, T. W., & Tournev, I. (2016). "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy. Journal of the Peripheral Nervous System, 21(1), 5–9. https://doi.org/10.1111/jns.12153
- Planté-Bordeneuve, V., & Said, G. (2011). Familial amyloid polyneuropathy. The Lancet Neurology, 10(12), 1086–1097. https://doi.org/10.1016/S1474-4422(11)70246-0